First Bank & Trust lifted its holdings in shares of Astrazeneca PLC (NYSE:AZN) by 7.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 46,593 shares of the company’s stock after purchasing an additional 3,194 shares during the period. Astrazeneca PLC accounts for 1.3% of First Bank & Trust’s holdings, making the stock its 18th biggest holding. First Bank & Trust’s holdings in Astrazeneca PLC were worth $1,578,000 as of its most recent SEC filing.
Several other large investors have also modified their holdings of AZN. Fisher Asset Management LLC lifted its holdings in shares of Astrazeneca PLC by 476.9% during the second quarter. Fisher Asset Management LLC now owns 11,081,856 shares of the company’s stock worth $377,780,000 after purchasing an additional 9,160,764 shares during the period. BlackRock Inc. lifted its holdings in shares of Astrazeneca PLC by 287,844.0% during the first quarter. BlackRock Inc. now owns 6,910,657 shares of the company’s stock worth $215,198,000 after purchasing an additional 6,908,257 shares during the period. Voya Investment Management LLC lifted its holdings in shares of Astrazeneca PLC by 38.2% during the second quarter. Voya Investment Management LLC now owns 2,395,465 shares of the company’s stock worth $81,661,000 after purchasing an additional 662,481 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Astrazeneca PLC by 746.0% during the second quarter. Russell Investments Group Ltd. now owns 620,901 shares of the company’s stock worth $21,167,000 after purchasing an additional 547,512 shares during the period. Finally, State Street Corp acquired a new position in shares of Astrazeneca PLC during the second quarter worth $14,536,000. Institutional investors own 14.18% of the company’s stock.
Astrazeneca PLC (AZN) traded down 0.12% during midday trading on Friday, hitting $33.49. 2,532,241 shares of the stock traded hands. The stock has a market capitalization of $84.80 billion, a P/E ratio of 21.97 and a beta of 0.76. Astrazeneca PLC has a 52 week low of $25.55 and a 52 week high of $35.60. The stock’s 50-day moving average price is $33.79 and its 200-day moving average price is $32.51.
Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.46. The company had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. Astrazeneca PLC’s quarterly revenue was down 9.9% compared to the same quarter last year. During the same period last year, the business earned $0.83 EPS. Equities research analysts expect that Astrazeneca PLC will post $1.91 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This report was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2017/10/29/first-bank-trust-acquires-3194-shares-of-astrazeneca-plc-azn.html.
A number of brokerages have recently commented on AZN. Piper Jaffray Companies reiterated a “buy” rating on shares of Astrazeneca PLC in a report on Wednesday, August 9th. Leerink Swann lifted their price target on shares of Astrazeneca PLC from $31.00 to $34.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. BidaskClub lowered shares of Astrazeneca PLC from a “sell” rating to a “strong sell” rating in a report on Friday, August 4th. Cowen and Company reiterated a “hold” rating and set a $37.00 price target on shares of Astrazeneca PLC in a report on Tuesday, October 17th. Finally, Citigroup Inc. upgraded shares of Astrazeneca PLC to a “buy” rating in a report on Wednesday, October 18th. Four equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and fifteen have given a buy rating to the stock. Astrazeneca PLC presently has an average rating of “Hold” and an average price target of $35.10.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).
What are top analysts saying about Astrazeneca PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Astrazeneca PLC and related companies.